OverviewSuggest Edit

Virios Therapeutics (formerly known as Innovative Med Concepts) is a biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia. Its lead candidate IMC-1 is a fixed-dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress herpes simplex virus-1 (HSV-1) activation and replication, with the end goal of reducing viral-mediated disease burden.

TypePublic
Founded2012
HQAlpharetta, GA, US
Websitevirios.com

Locations

Virios Therapeutics is headquartered in
Alpharetta, United States

Location Map

Latest Updates

Employees (est.) (Sept 2020)4
Share Price (Jun 2021)$6.1(-1%)
Cybersecurity ratingAMore

Key People/Management at Virios Therapeutics

Greg Duncan

Greg Duncan

Chief Executive Officer & Chairman of the Board of Directors
Ralph Grosswald

Ralph Grosswald

Vice President of Operations
Angela Walsh

Angela Walsh

Vice President of Finance & Treasurer
R. Michael Gendreau

R. Michael Gendreau

Chief Medical Officer
Richard Burch

Richard Burch

Director
Show more

Virios Therapeutics Office Locations

Virios Therapeutics has an office in Alpharetta
Alpharetta, GA, US (HQ)
44 Milton Ave
Show all (1)

Virios Therapeutics Financials and Metrics

Virios Therapeutics Revenue

USD

Net income (Q1, 2021)

(3.1m)

EBIT (Q1, 2021)

(3.1m)

Market capitalization (11-Jun-2021)

51.1m

Closing stock price (11-Jun-2021)

6.1

Cash (31-Mar-2021)

24.6m
Virios Therapeutics's current market capitalization is $51.1 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

1.1m1.3m

R&D expense

854.1k836.2k

Operating expense total

2.0m2.2m

EBIT

(2.0m)(2.2m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

General and administrative expense

343.5k2.6m1.4m

R&D expense

392.8k108.1k1.7m

Operating expense total

736.3k2.7m3.1m

EBIT

(736.3k)(2.7m)(3.1m)
Annual
USDFY, 2018FY, 2019

Cash

30.0k309.4k

Prepaid Expenses

12.0k5.7k

Current Assets

42.4k315.9k

Total Assets

65.9k315.9k
Quarterly
USDQ3, 2020Q1, 2021

Cash

499.1k24.6m

Prepaid Expenses

61.0k3.7m

Current Assets

560.1k28.3m

Total Assets

785.4k28.3m
Annual
USDFY, 2018FY, 2019

Net Income

(2.1m)(2.5m)

Accounts Payable

65.6k(89.8k)

Cash From Operating Activities

(1.2m)(2.1m)

Cash From Financing Activities

1.2m2.4m
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(1.8m)(3.8m)(3.1m)

Accounts Payable

(74.3k)156.1k530.8k

Cash From Operating Activities

(1.6m)(1.6m)(5.1m)

Cash From Financing Activities

1.8m1.8m(97.6k)
Show all financial metrics

Virios Therapeutics Operating Metrics

Nov, 2020

Patents (US)

12

Patents (Foreign)

8
Show all operating metrics

Virios Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Virios Therapeutics Online and Social Media Presence

Embed Graph

Virios Therapeutics Frequently Asked Questions

  • When was Virios Therapeutics founded?

    Virios Therapeutics was founded in 2012.

  • Who are Virios Therapeutics key executives?

    Virios Therapeutics's key executives are Greg Duncan, Ralph Grosswald and Angela Walsh.

  • How many employees does Virios Therapeutics have?

    Virios Therapeutics has 4 employees.

  • Who are Virios Therapeutics competitors?

    Competitors of Virios Therapeutics include Vcanbio Cell & Gene Engineering, Holostem and Polyplus-transfection.

  • Where is Virios Therapeutics headquarters?

    Virios Therapeutics headquarters is located at 44 Milton Ave, Alpharetta.

  • Where are Virios Therapeutics offices?

    Virios Therapeutics has an office in Alpharetta.

  • How many offices does Virios Therapeutics have?

    Virios Therapeutics has 1 office.